Genomics

Juniper Research: Precision Medicine Spend to Exceed $132 Billion Globally by 2027; Driven by Efficiency Gains for Healthcare Providers

Retrieved on: 
Tuesday, November 15, 2022
Technology, Surgery, Medical Devices, Software, Biotechnology, Hardware, Health, Pharmaceutical, Artificial Intelligence, Growth, Precision medicine, Research, Privacy, Genomics, AI, Face, Pharmaceutical industry, Medical device

A new study from Juniper Research found that the total spend on precision medicine will reach $132.3 billion globally by 2027; increasing from only $35.7 billion in 2022.

Key Points: 
  • A new study from Juniper Research found that the total spend on precision medicine will reach $132.3 billion globally by 2027; increasing from only $35.7 billion in 2022.
  • This strong growth of 270% is a result of emerging technologies and infrastructure, such as AI, which aids precision medicine by predicting risks for certain diseases.
  • These technological advancements, combined with the healthcare sectors need to increase efficiencies in the face of an economic downturn, will encourage healthcare providers to invest further into precision medicine.
  • Precision medicine leverages advances in personal genomics to enable healthcare providers to prepare preventative plans and disease treatments based on gene variability.

IonOpticks ushers in a new age of proteomics with Aurora Frontier

Retrieved on: 
Thursday, November 24, 2022
Aurora, LC-MS, MTV Music Generator 3: This Is the Remix, Medical research, Life, Infection, Disease, Mass spectrometry, Alzheimer's disease, Drug discovery, Environment, Proteomics, Frontier, Protein, Diagnosis, Health, File association, WEHI, Genomics, Walter, UHPLC, IDS, Biology, Research, Proteome, Associate, Management, Fine chemical, Pharmaceutical industry

MELBOURNE, Australia, Nov. 23,2022 /PRNewswire/ -- The field of proteomics is set to be revolutionised with the launch today of IonOpticks' Aurora Frontier that achieves more than 10,000 proteins per sample.

Key Points: 
  • MELBOURNE, Australia, Nov. 23,2022 /PRNewswire/ -- The field of proteomics is set to be revolutionised with the launch today of IonOpticks' Aurora Frontier that achieves more than 10,000 proteins per sample.
  • Proteomics is the final frontier in allowing us to understand biology to a level that enables us to fully understand and manipulate disease," says Assoc.
  • "Frontier allows researchers to get as much as possible from their samples, whichare often precious and very labour-intensive to generate.
  • Frontier is part of IonOpticks' Aurora Series and follows the launch of its Generation 3 product base which launched the highest-performing and most user-friendly UHPLC columns available.

The global laboratory informatics market was valued at $4,341.2 million in 2021 and is anticipated to reach $12,677.0 million by 2032, witnessing a CAGR of 10.27% during the forecast period 2022-2032

Retrieved on: 
Tuesday, November 22, 2022
Drug development, Agilent Technologies, COVID-19, HIPAA, Genomics, Coronavirus, LIMS, ELN, Research, Danaher, FDA, CLIA, Growth, CDC, Data management, IDBS, Laboratory, Thermo Fisher Scientific, Software, Informatics, Fine chemical, Medicine, Pharmaceutical industry

View original content:https://www.prnewswire.com/news-releases/the-global-laboratory-informati...

Key Points: 
  • The global laboratory informatics market was valued at $4,341.2 million in 2021 and is anticipated to reach $12,677.0 million by 2032, witnessing a CAGR of 10.27% during the forecast period 2022-2032.
  • The growth in the global laboratory informatics market is expected to be driven by the increased efficiency of laboratories due to their usage and better data management.
  • This expanded usage of laboratory informatics has enabled end customers to describe particular system requirements, prompting suppliers to design more appealing and practical products and feasible laboratory informatics choices.
  • The presence of major instrument providers of laboratory informatics has a major impact on the market.

Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer's Disease

Retrieved on: 
Monday, November 21, 2022
Doctor of Philosophy, Head, AD, Dementia, MD, University of Siena, Biomarker, Foreign policy, Precision medicine, University, Clinical trial, Blood, University of Cambridge, Research, Dhaneswar Rath Institute of Engineering and Management Studies, Novartis, Government budget balance, CFO, Biology, Patient, Sanofi, GlaxoSmithKline, Diagnosis, CMO, University of Glasgow, Molecular medicine, Chartered accountant, Disease, Genomics, Laboratory, Management, Pharmaceutical industry, Medical device, Medical imaging, Teva, Alzheimer's disease, EU, Engineering, Takeda, Operation, Diadem

MILAN, Nov. 21, 2022 /PRNewswire/ -- Diadem SpA, (or Diadem US, Inc.) a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced key additions to its senior management team. Sam Agus, MD, has been appointed Chief Medical Officer (CMO), James Clarke, PhD, has been named Head, External Affairs and Collaborations, and Peter Bream is Diadem's new Chief Financial Officer (CFO). They join Simona Piccirella, PhD, Vice President of Operations and Development and Chief Executive Officer Paul Kinnon at Diadem.

Key Points: 
  • They join Simona Piccirella, PhD, Vice President of Operations and Developmentand Chief Executive Officer Paul Kinnon at Diadem.
  • Simona has already played a major role in growing Diadem and developing the AlzoSure technology to this stage.
  • Their contributions will be instrumental as we prepare for the commercialization of AlzoSure Predict in the new year."
  • The company is also developing AlzoSure Confirm, a blood-based diagnostic test for AD that has shown promising results in early studies.

New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL

Retrieved on: 
Friday, November 18, 2022
Ecosystem, Nobel Prize, Innovation, CRISPR, Heart, Enzyme, Biofuel, Research, Genomics, Sale, GMP, Multimedia, D, CVC, Cas9, ERS, Synthetic biology, Pharmaceutical industry, Fine chemical

DUBLIN, Nov. 17, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce ATLATL Innovation Centre ('ATLATL') as its non-exclusive agent for licensing ERS' intellectual property for commercial and/or research use in China.

Key Points: 
  • DUBLIN, Nov. 17, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce ATLATL Innovation Centre ('ATLATL') as its non-exclusive agent for licensing ERS' intellectual property for commercial and/or research use in China.
  • ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property.
  • Eric Rhodes, CEO at ERS Genomics, made the following statement:"With an ever-expanding portfolio of CRISPR/Cas9 technology patents, including more recent grants in China, ERS is pleased and honored to be partnering with ATLATL to make CRISPR/Cas9 more accessible worldwide.
  • Media contact: Dara O'Donnell ERS Genomics Tel: + 353-1-539 0083
    About ERS GenomicsFreedom to operate with CRISPR/Cas9 technology begins with a license to the foundational CVC patents available from ERS Genomics.

New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL

Retrieved on: 
Friday, November 18, 2022
Ecosystem, Nobel Prize, Innovation, CRISPR, Heart, Enzyme, Biofuel, Research, Genomics, Sale, GMP, D, CVC, Cas9, ERS, Synthetic biology, Pharmaceutical industry, Fine chemical

DUBLIN, Nov. 18, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce ATLATL Innovation Centre ('ATLATL') as its non-exclusive agent for licensing ERS' intellectual property for commercial and/or research use in China.

Key Points: 
  • DUBLIN, Nov. 18, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce ATLATL Innovation Centre ('ATLATL') as its non-exclusive agent for licensing ERS' intellectual property for commercial and/or research use in China.
  • ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property.
  • Eric Rhodes, CEO at ERS Genomics, made the following statement:"With an ever-expanding portfolio of CRISPR/Cas9 technology patents, including more recent grants in China, ERS is pleased and honored to be partnering with ATLATL to make CRISPR/Cas9 more accessible worldwide.
  • Media contact: Dara O'Donnell ERS Genomics Tel: + 353-1-539 0083
    About ERS GenomicsFreedom to operate with CRISPR/Cas9 technology begins with a license to the foundational CVC patents available from ERS Genomics.

Kalorama Information: 20 Companies That Have Worked Out Molecular Diagnostic Deals Recently

Retrieved on: 
Thursday, November 17, 2022
Knowledge, Medicine, Bio-Rad Laboratories, Knowledge-centered support, Biotechnology, Partnership, Single-cell analysis, Software, Consortium, Roche, Genomics, AstraZeneca, LRRK2, NGS, IVD, Exact sciences, Patient, Parkinson's disease, Biosensor, Curiosity, SD, Brain, Architecture, Medical device, Medical imaging, Pharmaceutical industry, Antibiotics, Science, Ultima, Meridian, Pirch (company)

ARLINGTON, Va., Nov. 17, 2022 /PRNewswire-PRWeb/ -- According to Kalorama Information's The World Market for Molecular Diagnostics Tests, 11th Edition, the demand for molecular in vitro diagnostics (IVD) means that very often a single firm cannot go it alone and must find partners.

Key Points: 
  • The demand for molecular in vitro diagnostics (IVD) means that often a single firm cannot go it alone and must find partners.
  • Here are 10 key recent deals in the market.
  • Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals.
  • Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology.

ARK Invest and BMO Investments Inc. Launch Three of ARK's Existing ETF Strategies Available for Canadian Investors

Retrieved on: 
Thursday, November 17, 2022
ARK, ARKK, Investment, Robotics, Growth, Innovation, Toronto Stock Exchange, Ark Invest, CRISPR, ETF, Therapy, ARKW, B cell, Partnership, ARKG, History, Fund, Research, BMO, Science and technology in Asia, Artificial intelligence, Life, Internet, Venture capital, Genomics, 3D printing, Financial adviser, Renewable energy

ST. PETERSBURG, Fla., Nov. 17, 2022 /PRNewswire/ -- ARK Investment Management LLC ("ARK" or "ARK Invest"), is pleased to announce its partnership with BMO Investments Inc., the manager of the BMO Mutual Funds, to make three of ARK's existing ETF strategies available to investors in Canada.

Key Points: 
  • ST. PETERSBURG, Fla., Nov. 17, 2022 /PRNewswire/ -- ARK Investment Management LLC ("ARK" or "ARK Invest"), is pleased to announce its partnership with BMO Investments Inc., the manager of the BMO Mutual Funds, to make three of ARK's existing ETF strategies available to investors in Canada.
  • The three new BMO ARK mutual funds, with ETF Series listed on the Toronto Stock Exchange, are BMO ARK Innovation Fund (ARKK), BMO ARK Genomic Revolution Fund (ARKG), and BMO ARK Next Generation Internet Fund (ARKW) (collectively, the "BMO ARK Funds").
  • "Leveraging BMO's powerful scale and distribution network, we are proud to make our existing ETF strategies available for more investors in Canada by launching the BMO ARK Funds," said Cathie Wood, ARK's Chief Executive Officer and Chief Investment Officer.
  • Today's listing of the new BMO ARK Funds builds on BMO Exchange Traded Funds comprehensive suite of strategies across mandates, asset classes, and geographies, providing effective portfolio solutions for investors.

Global Synthetic Biology Market to Reach $52.04 Billion by 2028 at a CAGR of 27.89%

Retrieved on: 
Thursday, November 17, 2022
Acid, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, VPS, Synthetic biology, Primary, Xeno, Biology, Biotechnology, Genome, Medicine, DNA synthesis, Biosecurity, Analysis, R, Marketing, Research, MEA, DNA, Risk, USD, Core product, Nanotechnology, Engineering, Enzyme, Genomics, Science and technology, Tool, Fine chemical, Environment, Science, Application, Microfluidics, Health care, Oligonucleotide, Sequencing, Agriculture, Food

The Global Synthetic Biology Market is valued at USD 9.3 Billion in 2021, and it is anticipated to attain a value of USD 52.04 Billion by 2028, at a CAGR of 27.89 % over the forecast period (2022 - 2028).

Key Points: 
  • The Global Synthetic Biology Market is valued at USD 9.3 Billion in 2021, and it is anticipated to attain a value of USD 52.04 Billion by 2028, at a CAGR of 27.89 % over the forecast period (2022 - 2028).
  • The interdisciplinary field of synthetic biology deals with the application of engineering concepts to biology.
  • Synthetic biology has the potential to provide solutions to issues in agriculture, manufacturing, and medicine.
  • The global synthetic biology market is being driven by the application of synthetic biology techniques in medication discovery and development.

Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director

Retrieved on: 
Thursday, November 17, 2022
RESEARCH, Health, MBA, Physician, University, Master of Business Administration, PARK, Multimedia, Exact sciences, Patient, Noise, Business administration, Oncology, Foundation Medicine, Genomics, Management, Hospital, Northwestern University

CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 /PRNewswire/ -- Biofidelity, a revolutionary genomic technology company, has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director effective immediately.

Key Points: 
  • CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 /PRNewswire/ -- Biofidelity, a revolutionary genomic technology company, has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director effective immediately.
  • Matt brings extensive, relevant experience and a unique track record of driving revenue growth for genomics companies in both the specialty laboratory and distributed product manufacturing segments.
  • Regarding his appointment, Matt commented, "I am delighted to join Biofidelity at this very exciting time in the Company's journey.
  • Biofidelity is a revolutionary genomic technology company dedicated to removing the noise from genomic analysis to unleash its potential to transform human health.